Artificial Intelligence Articles
Featured Articles
Read our latest stories on the people and scientific innovations making a difference in patients’ lives.
How Pfizer Is Rethinking What’s Possible in Cancer Care
For people living with cancer and those who love them, every moment matters. Cancer remains one of the greatest healthcare challenges of our lifetime, and Pfizer is working with urgency to transform scientific advances into potential life-changing medicines.In a sponsored interview, Jeff Legos, Pfizer’s Chief Oncology Officer, sat down with Jessica Sibley, CEO of TIME, to discuss why this mission is personal for him, the responsibility he feels as Pfizer works toward its ambition of delivering...
Pfizer Learns to Speak AI with Fluency Program
Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI).Here at Pfizer, we have long been focused on making breakthroughs that change patients’ lives. As new technology like AI emerges that can help us pursue our goals, we are committed to learning how best to apply AI to help make those breakthroughs even more quickly and efficiently. CEO Albert Bourla is leading the way with his vision for the future of Pfizer. His goal is to leverage AI...
Bourla at Concordia: The Business of Better Health
Each September, government officials, global executives, NGOs and other key leaders converge on New York for the United Nations General Assembly. The week is marked by direct, cross-sector dialogues about the state of the world and how we can plan for a prosperous future.At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."As the global population ages...
How AI Is Helping Match Patients to Clinical Trials Faster
Long before reaching pharmacy shelves, every new medicine must complete one or more clinical trials. But before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.Patient enrollment is the cornerstone of every clinical trial, but it’s usually the longest phase of the process. Recruiting enough eligible...
August Social Media Round-Up—Q2 Results, AI Adoption, and More
Summer is coming to an end, but here at Pfizer, the work doesn’t stop when the seasons change. Before we say goodbye to the warmer weather, let’s take a look back at the month on Pfizer’s social media.In August, we highlighted the importance of our manufacturing systems, leveraged a new AI tool in our supply chain, and released a new episode of "What's In My Lab."Meanwhile, CEO Albert Bourla shared our second quarter results, shared how Pfizer is taking on AI adoption, and sat down with TIME...
Decoding Tumors: Inside the Spatial Revolution in Cancer Research
Cancer emerges from the very same cellular machinery that keeps us alive. It puzzles both pathologists and the immune system because tumors, unlike infections, share the basic structures and behavioral blueprints of healthy, normal tissue, a resemblance that can let them slip past immune surveillance undetected. For more than a century, cancer was described by pathologists as a “caricature” of healthy tissue, bizarre distortions of otherwise normal cells.1 But tumors act almost like organisms...
How Pfizer Thinks About AI
At Pfizer, our ambition is to be the most AI-forward company in our industry, and we are making great progress every day. I spend more time thinking about it than almost anything else because I believe this is an unprecedented opportunity. AI will fundamentally improve how we discover medicines, how we develop and manufacture them and how quickly we reach patients. Very few technologies can change every corner of a business in this way.AI adoption is one thing — nearly every company has done it...
July Social Media Round-Up—America 250, Pfizer Futures, and More
Even amidst the cookouts, fireworks, and vacations, Pfizer remains hard at work all summer long, and July was no different.Last month, we held important conversations around living with alopecia areata, shared the story of a Pfizer colleague and cancer survivor, and reflected on the changes in science over the years.CEO Albert Bourla celebrated America’s 250th birthday, shared advice for our outgoing Pfizer Futures class, and congratulated the World Cup winners. While our leadership team shared...
June Social Media Round-Up—2025 Impact Report, ADA 2026, and More
School is out for the summer, but Pfizer colleagues are still hard at work. In June, we released our 2025 Impact Report, shared risks of fake medicines on World Anti-Counterfeit Day, and raised awareness of menstrual-related migraine and more.Pfizer has also been present at many conferences this past month—from ASCO and ADA to EHA and AHS 2026, and our leadership team has been highlighting the latest data that we’ve shared at these events. Meanwhile, CEO Albert Bourla joined the CNBC CEO Council...
May Social Media Round-Up—ASCO, Q1 2026 Results, and More
Summer’s approaching fast, but here at Pfizer the work doesn’t stop. So before you get outside to enjoy the warmer weather, catch up with the latest activity on our social channels.May has been chock full of highlights—from sharing the latest data across our cancer work at ASCO 2026 to a feature in TIME highlighting how we bring science from the lab to life, we’re offering looks behind the science of Pfizer’s research. Next, review Pfizer’s first quarter results, courtesy of CEO Albert Bourla...
Building an AI-Fluent Organization: How Pfizer is helping colleagues understand, embrace, and apply AI
Pfizer has been utilizing artificial intelligence (AI) across our business for some time, but recent advancements in technology combined with advancements in biology are converging to create a scientific renaissance set to transform health as we know it. That reality is already upon us.According to Pfizer CEO Albert Bourla, the biggest barrier to unlock this potential is fear of the unknown. "It is not a question of technology," Bourla said in a recent conversation with Nikolai Tangen of the...
April Social Media Round-Up—Trailblazer Cancer Research Grants, World Health Day, and More
April has come to a close and we are barreling towards the summer. Before you head outside to enjoy spring, take a moment to catch up with Pfizer’s social channels, which have been on fire.In April, Pfizer colleagues were honored in the list of 2026 Healthcare Businesswomen’s Association (HBA) Luminaries and Rising Stars, we recognized vaccines’ impact during World Immunization Week, and Pfizer scientists highlighted our research efforts.CEO Albert Bourla recognized Pfizer scientists who were...
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits. However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer Media Contacts may only respond to calls and emails from professional journalists.